[go: up one dir, main page]

NO20090425L - Sammensetning, egnet for oral administration, inneholdende et triazolo [4,5-D] pyrimidin derivat - Google Patents

Sammensetning, egnet for oral administration, inneholdende et triazolo [4,5-D] pyrimidin derivat

Info

Publication number
NO20090425L
NO20090425L NO20090425A NO20090425A NO20090425L NO 20090425 L NO20090425 L NO 20090425L NO 20090425 A NO20090425 A NO 20090425A NO 20090425 A NO20090425 A NO 20090425A NO 20090425 L NO20090425 L NO 20090425L
Authority
NO
Norway
Prior art keywords
triazolo
oral administration
composition suitable
pyrimidine derivative
administration containing
Prior art date
Application number
NO20090425A
Other languages
English (en)
Other versions
NO341787B1 (no
Inventor
Simon Banks
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39107049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090425(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20090425L publication Critical patent/NO20090425L/no
Publication of NO341787B1 publication Critical patent/NO341787B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Foreliggende oppfinnelse angår farmasøytiske preparater og mer spesielt et farmasøytisk preparat inneholdende forbindelsen {1S-[1a, 2a, 3ß (1S*,2R*),5ß]}-3-(7-{[2-(3,4-difluorfenyl)cyklopropyl]amino}-5-(propyltio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroksyetoksy)cyklopentan-1,2-diol.
NO20090425A 2006-08-21 2009-01-28 Farmasøytisk preparat omfattende et triazolo [4,5-D] pyrimidin derivat NO341787B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82308306P 2006-08-21 2006-08-21
PCT/SE2007/000736 WO2008024045A1 (en) 2006-08-21 2007-08-20 Compositions, suitable for oral administration, comprising a triazolo [4, 5-d]pyrimidin derivate

Publications (2)

Publication Number Publication Date
NO20090425L true NO20090425L (no) 2009-03-05
NO341787B1 NO341787B1 (no) 2018-01-22

Family

ID=39107049

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090425A NO341787B1 (no) 2006-08-21 2009-01-28 Farmasøytisk preparat omfattende et triazolo [4,5-D] pyrimidin derivat

Country Status (35)

Country Link
US (2) US8425934B2 (no)
EP (1) EP2056832B1 (no)
JP (2) JP5385139B2 (no)
KR (1) KR101539467B1 (no)
CN (1) CN101505754A (no)
AR (1) AR062451A1 (no)
AU (2) AU2007288541B9 (no)
BR (1) BRPI0715712B8 (no)
CA (1) CA2659328C (no)
CL (1) CL2007002421A1 (no)
CO (1) CO6150163A2 (no)
CY (1) CY1119380T1 (no)
DK (1) DK2056832T3 (no)
ES (1) ES2625930T3 (no)
HR (1) HRP20170694T1 (no)
HU (1) HUE031939T2 (no)
IL (2) IL196700A (no)
LT (1) LT2056832T (no)
MX (1) MX340403B (no)
MY (2) MY147966A (no)
NO (1) NO341787B1 (no)
NZ (2) NZ574514A (no)
PH (1) PH12013501627A1 (no)
PL (1) PL2056832T3 (no)
PT (1) PT2056832T (no)
RS (1) RS55884B1 (no)
RU (2) RU2476223C2 (no)
SA (1) SA07280442B1 (no)
SG (1) SG177162A1 (no)
SI (1) SI2056832T1 (no)
TW (1) TWI482772B (no)
UA (1) UA99105C2 (no)
UY (1) UY30551A1 (no)
WO (1) WO2008024045A1 (no)
ZA (1) ZA200900991B (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
PL1917253T3 (pl) 2005-08-15 2015-06-30 Boehringer Ingelheim Int Sposób wytwarzania betamimetyków
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
ES2548845T3 (es) 2009-12-23 2015-10-21 Ratiopharm Gmbh Forma de dosificación farmacéutica sólida de ticagrelor y ácido acetilsalicílico
CZ2012705A3 (cs) * 2012-10-16 2014-04-23 Zentiva, K.S. Pevná orální farmaceutická formulace obsahující ticagrelor
WO2014170026A1 (en) 2013-04-18 2014-10-23 Zentiva, K.S. Stabilized amorphous ticagrelor
EP2813216A1 (en) 2013-06-10 2014-12-17 Zentiva, a.s. Stabilized amorphous ticagrelor
CA2913326A1 (en) 2013-05-29 2014-12-04 Ratiopharm Gmbh Solid pharmaceutical dosage form
EP2816043A1 (en) 2013-06-21 2014-12-24 LEK Pharmaceuticals d.d. Spherical ticagrelor particles
WO2015001489A1 (en) 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Pharmaceutical compositions of ticagrelor
CZ2013866A3 (cs) 2013-11-08 2015-05-20 Zentiva, K.S. Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru
CN104644604A (zh) * 2013-11-23 2015-05-27 天津市汉康医药生物技术有限公司 替格瑞洛倍半水合物胶囊及其制备方法
WO2015110952A1 (en) 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof
CN104940204A (zh) * 2014-03-27 2015-09-30 广东东阳光药业有限公司 一种替格瑞洛固体制剂及其制备方法
CN104098520B (zh) * 2014-07-23 2016-01-20 张远强 苯基三唑希夫碱类化合物、其制备方法和用途
KR20160012706A (ko) 2014-07-25 2016-02-03 동아에스티 주식회사 서방성 제제
CN105832683A (zh) * 2015-01-15 2016-08-10 成都国弘医药有限公司 一种含有替格瑞洛的片剂
JP2018502894A (ja) * 2015-01-27 2018-02-01 アストラゼネカ アクチボラグ 心筋梗塞の病歴がある患者においてアテローム血栓性イベントを治療または予防する方法
WO2017106328A1 (en) * 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3389652B1 (en) 2015-12-14 2022-09-28 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN108883091A (zh) 2015-12-22 2018-11-23 X4 制药有限公司 用于治疗免疫缺陷病的方法
CN105709230B (zh) * 2016-03-01 2019-05-31 北京鑫兰医药科技有限公司 一种替格瑞洛药物组合物及其制备方法
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
US20170296666A1 (en) 2016-04-18 2017-10-19 Amneal Pharmaceuticals Company Gmbh Stable Pharmaceutical Composition Of Amorphous Ticagrelor
SG10202107682QA (en) * 2016-04-21 2021-08-30 Astrazeneca Ab Orally disintegrating tablets
JP7084624B2 (ja) 2016-06-21 2022-06-15 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
EP3472129A4 (en) 2016-06-21 2019-12-04 X4 Pharmaceuticals, Inc. CXCR4 INHIBITORS AND USES THEREOF
WO2017223239A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
TR201617983A2 (tr) 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Ti̇cagrelorun kati oral farmasöti̇k bi̇leşi̇mleri̇
WO2019170244A1 (en) 2018-03-08 2019-09-12 Pharmaceutical Oriented Services Ltd. Ticagrelor—containing tablet formulation
WO2020021110A1 (en) 2018-07-27 2020-01-30 Krka, D.D., Novo Mesto Pharmaceutical composition of ticagrelor
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN115515585A (zh) 2020-03-10 2022-12-23 X4 制药有限公司 用于治疗中性粒细胞减少症的方法
JP7657041B2 (ja) 2020-08-19 2025-04-04 アストラゼネカ・アクチエボラーグ 併用療法
US20240285636A1 (en) * 2021-06-14 2024-08-29 Libbs Farmacêutica Ltda Pharmaceutical composition and use of the pharmaceutical composition
WO2024089196A1 (en) 2022-10-28 2024-05-02 Astrazeneca Ab Recombinant apyrase protein for use in the treatment of an ischemic event at a dose of 40-240 mg

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9904129D0 (sv) 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
CN1668282A (zh) * 2001-12-21 2005-09-14 辉瑞产品公司 可直接压制的阿齐霉素配方
PL373694A1 (en) 2002-02-15 2005-09-05 Teva Gyogyszergyar Reszvenytarsasag Powder composition comprising zaleplon of defined particle size distribution and pharmaceutical products made therefrom
US20040001885A1 (en) * 2002-06-27 2004-01-01 Unchalee Kositprapa Rapidly disintegrating antihistamine formulation
HN2003000272A (es) * 2002-09-10 2008-07-29 Pharmacia Italia Spa Formulaciones que comprenden un compuesto de indolinona
WO2004032905A1 (en) 2002-10-08 2004-04-22 Ranbaxy Laboratories Limited Gabapentin tablets and methods for their preparation
EP1556050A1 (en) 2002-10-22 2005-07-27 Ranbaxy Laboratories Limited Pharmaceutical compositions of ganciclovir
SE0203778D0 (sv) * 2002-12-09 2002-12-09 Astrazeneca Ab A new oral immediated release dosage form
JP2005538038A (ja) * 2003-02-19 2005-12-15 テバ ジョジセルジャール レースベニュタールシャシャーグ 規定された粒子サイズの分布を持つザレプロンを含む粉末組成物、及びそれから作られた医薬製品
DE10319450A1 (de) 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
JP2005162696A (ja) * 2003-12-04 2005-06-23 Nichiko Pharmaceutical Co Ltd 溶出性に優れたセフジトレンピボキシル製剤
EP1747016A2 (en) 2004-05-13 2007-01-31 Boehringer Ingelheim International GmbH Use of dipyridamole for treatment of resistance to platelet inhibitors
WO2006072878A1 (en) 2005-01-07 2006-07-13 Ranbaxy Laboratories Limited Oral dosage forms of sertraline having controlled particle size and processes for their preparation
KR101203118B1 (ko) * 2005-01-31 2012-11-20 옵티머 파마슈티칼즈, 인코포레이티드 18-원자 거대고리들 및 그 유사체들
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物

Also Published As

Publication number Publication date
MX340403B (es) 2016-07-07
PT2056832T (pt) 2017-05-22
PL2056832T3 (pl) 2017-09-29
DK2056832T3 (en) 2017-05-22
PH12013501627A1 (en) 2014-11-10
TW200817412A (en) 2008-04-16
NZ596700A (en) 2013-05-31
EP2056832A1 (en) 2009-05-13
CA2659328A1 (en) 2008-02-28
CO6150163A2 (es) 2010-04-20
BRPI0715712A2 (pt) 2014-06-24
WO2008024045A1 (en) 2008-02-28
NZ574514A (en) 2012-01-12
AU2007288541A1 (en) 2008-02-28
CY1119380T1 (el) 2018-02-14
HUE031939T2 (en) 2017-08-28
SG177162A1 (en) 2012-01-30
CN101505754A (zh) 2009-08-12
SA07280442B1 (ar) 2012-04-07
BRPI0715712B1 (pt) 2021-03-23
RU2009104330A (ru) 2010-09-27
RU2012153069A (ru) 2014-06-10
BRPI0715712B8 (pt) 2021-05-25
SI2056832T1 (sl) 2017-07-31
AU2011205164B2 (en) 2014-02-06
IL196700A0 (en) 2009-11-18
CL2007002421A1 (es) 2008-04-04
AU2007288541B2 (en) 2011-08-25
LT2056832T (lt) 2017-05-25
AU2011205164A1 (en) 2011-08-25
ZA200900991B (en) 2010-02-24
IL229130A0 (en) 2013-12-31
MY175009A (en) 2020-06-02
JP2014040448A (ja) 2014-03-06
MY147966A (en) 2013-02-28
AU2007288541B9 (en) 2011-10-06
RS55884B1 (sr) 2017-08-31
JP5385139B2 (ja) 2014-01-08
US20130131087A1 (en) 2013-05-23
UY30551A1 (es) 2008-03-31
UA99105C2 (ru) 2012-07-25
JP2010501554A (ja) 2010-01-21
EP2056832B1 (en) 2017-03-22
RU2476223C2 (ru) 2013-02-27
ES2625930T3 (es) 2017-07-21
AR062451A1 (es) 2008-11-12
MX2009001853A (es) 2009-03-02
US8425934B2 (en) 2013-04-23
NO341787B1 (no) 2018-01-22
KR20090055561A (ko) 2009-06-02
KR101539467B1 (ko) 2015-07-24
HRP20170694T1 (hr) 2017-07-28
TWI482772B (zh) 2015-05-01
EP2056832A4 (en) 2012-12-26
IL196700A (en) 2014-08-31
CA2659328C (en) 2015-08-11
US20080058353A1 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
NO20090425L (no) Sammensetning, egnet for oral administration, inneholdende et triazolo [4,5-D] pyrimidin derivat
TW200744602A (en) Administration of dipeptidyl peptidase inhibitors
MX2021003241A (es) Sal de tosilato de pirrolo[2,3-d]pirimidina, forma cristalina de la misma y proceso de fabricacion e intermediario al mismo.
HRP20181912T1 (hr) Derivati pirolo[2,3-d]pirimidina kao inhibitori janus kinaze
JO2534B1 (en) Pyrimidines carrying alternatives of sulfoximine as CDK and / or VEGF inhibitors and their production and use as pharmaceutical agents
EA201170771A1 (ru) Органические соединения
EA200701854A1 (ru) Соединения - ингибиторы дипептидилпептидазы-iv, способы их получения, а также фармацевтические композиции, содержащие указанные соединения в качестве активного ингредиента
MX2009002772A (es) Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro- 2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo.
HN2008001530A (es) Compuestos de amino pirimidina 2,6- sustituidos -4-monosustituidos como antagonistas del receptor de prostaglandina d2
TN2011000245A1 (en) Organic compounds
DE602005014086D1 (de) Pyrimidinderivate als orexin-rezeptorantagonisten
WO2006078676A3 (en) Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
IN2012DN02577A (no)
DK1869049T3 (da) Imidazopyridazinforbindelser
UA92756C2 (ru) Производные пиразоло[1,5-альфа]пиримидинила, полезные как антагонисты рецептора рилизинг-фактора кортикотропина (crf)
PA8568401A1 (es) Inhibidores pirimidina y piridina biciclicos de la p38 quinasa
ATE514694T1 (de) 2-amino-7,8-dihydro-6h-pyrido(4,3-d)pyrimidin-5 one, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
TN2009000362A1 (en) Weekly administration of dipeptidyl peptidase inhibitors
PE20090944A1 (es) PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT
MA44720B1 (fr) Comprimés à désintégration orale
UA95230C2 (ru) ЗАМЕЩЕННЫЕ ТЕТРАГИДРОПИРИМИДО[4,5-d]ПИРИМИДИНЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИХ, И ИХ ПРИМЕНЕНИЕ
CY1111644T1 (el) Τριαζολο [1,5-α] κινολινες ως συνδετες του υποδοχεα a3 της αδενοσινης
JO2770B1 (en) Organic compounds
EA200600688A1 (ru) Арилинденпиридины и арилинденпиримидины и их применение в качестве антагонистов аденозинового рецептора а2а
DK1742950T3 (da) Pyrazolo-[4,3-D]-pyrimidiner